| Date | Title | Description |
| 10.01.2018 | Lummy Invests $1.5 Million in Argos Therapeutics | Argos Therapeutics Inc., biotechnology company headquartered in Durham, North Carolina, announced that a Hong Kong company purchased 7.5 million shares of stock for $1.5 million, according to a filing with the Securities and Exchange Commis... |
| 10.01.2018 | Lummy Invests $1.5 Million in Argos Therapeutics | Argos Therapeutics Inc., biotechnology company headquartered in Durham, North Carolina, announced that a Hong Kong company purchased 7.5 million shares of stock for $1.5 million, according to a filing with the Securities and Exchange Commis... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 08.03.2016 | Argos Therapeutics Announces Financing of Up to $60 Million | DURHAM, N.C., March 07, 2016 (GLOBE NEWSWIRE) — Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cance... |
| 17.07.2015 | Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 | Fully Personalized Immunotherapy is Being Evaluated in Combination With Standard Targeted Therapy for the Treatment of Newly Diagnosed Metastatic Renal Cell Carcinoma
DURHAM, N.C., July 15, 2015 (GLOBE NEWSWIRE) — Argos Therapeutics Inc. (... |
| 20.02.2014 | TVM Capital Life Science counts two successful biotech IPOs of portfolio in the U.S. market in the last two weeks – which brings the total to four IPOs within 10 months, raising $ 300 million | Munich, Montreal, February 19, 2014 — Biotech IPOs continue to roll on and it is an explicit pleasure for TVM Capital Life Science as an investor to be part of the now year-long biotech IPO boom on NASDAQ which is one of the busiest IPO per... |
| 21.11.2013 | Argos Therapeutics Inks Additional $17.5M of Series E |
DURHAM, NC, Biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases increased the size of its previously announced Series E finan... |
| 20.11.2013 | Argos Therapeutics Raises $17.5M in Series E Financing | Argos Therapeutics Inc., a Durham, North Carolina-based biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ ... |
| 28.08.2013 | Argos Therapeutics Secures $42.5 Million Financing, Funds Pivotal Phase 3 ADAPT Trial for Personalized Immunotherapy | Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today an... |
| 28.08.2013 | Argos Therapeutics Secures $42.5M in Series E Financing | Argos Therapeutics Inc., a Durham, North Carolina-based biopharmaceutical company focused on the development and commercialization of immunotherapies, secured $42.5m in Series E financing.
The round was led by Pharmstandard International S.... |
| 26.08.2013 | Argos Therapeutics Secures $42.5M |
DURHAM, NC, Biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies has secured $42.5 million in a Series E financing.
>> Click here for more funding data on Argos Therapeuti... |
| 26.08.2013 | Argos Therapeutics Secures $42.5 Million Financing, Funds Pivotal Phase 3 ADAPT Trial for Personalized Immunotherapy | Lead Investor Pharmstandard Commits $30 Million and Receives Russian Commercialization Rights
DURHAM, N.C. – August 26, 2013 – Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully p... |
| 15.01.2013 | Personalized immunotherapy could signal first combination treatment for renal cell carcinoma patients | CEO Jeff Abbey told MedCity News that more than 50 percent of patients in a phase 2 study for the therapy survived longer than 30 months — nearly four times the expected long-term survival rate for sunitinib in similar risk patients, accord... |
| 13.01.2013 | Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study | Learn More-External Link |
| 08.06.2012 | Experimental lupus therapy from Argos in partnering talks after strong phase 1 | Argos had planned to support its drug development efforts pipeline with an initial public stock offering that was filed last year that could have raised $65 million. But the company withdrew those plans in March and cited market conditions.... |
| 07.06.2012 | Argos Therapeutics Presents Positive Phase 1a Data for AGS-009 in Patients with Lupus | Learn More-External Link |
| 24.04.2012 | Argos raises $25M for kidney cancer immunotherapy phase 3 study | Full phase 2 results of AGS-003 were reported in February. Those results showed that when used with sunitinib, a cancer drug that is the standard of care for renal cell carcinoma, the combination prolonged survival and also showed that the ... |
| 24.04.2012 | Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012 | –Arcelis™ Immunotherapy AGS-003 Granted U.S. FDA Fast Track Designation for Treatment of mRCC– Durham, NC– April 24, 2012 —Argos Therapeutics Inc. today announced that it has secured a $25 million Series D financing to support the commencem... |
| 24.04.2012 | Argos Therapeutics Raises $25M in Series D Financing | Argos Therapeutics, a Durham, North Carolina-based biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases, has raised $25m in Seri... |
| 24.04.2012 | Argos Therapeutics Secures $25 million Series D Financing | Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
–Arcelis™ Immunotherapy AGS-003 Granted U.S. FDA Fast Track Designation for Treatm... |
| 07.03.2012 | No IPO for immunotherapy company Argos Therapeutics | But the public markets have remained cool to life science IPOs. Merrimack Pharmaceuticals, a a Cambridge, Massachusetts firm developing cancer treatments, last month postponed its $80 million IPO. Chapel Hill, North Carolina-based Cempra Ph... |
| 04.02.2012 | Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis™ Immunotherapy AGS-003 | SOURCE: Argo Therapeutics |
| 31.01.2012 | Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients wi... | Learn More-External Link |
| 29.07.2011 | Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering | Learn More-External Link |
| 29.07.2011 | Argos Therapeutics IPO would raise up to $86 million | Argos’ immunotherapy technology, called Arcelis, induces a patient’s own immune system to fight disease. Besides applications in treating cancer, Argos is also researching Arcelis as a way to fight HIV.
Argos was founded in 1998 as Merix Bi... |
| 29.07.2011 | What Argos Therapeutics plans to do with $86M from an IPO | Proceeds from the stock offering will be used to finance trials that will test lead product candidate AGS-003 in combination with Pfizer (NYSE:PFE) drug sunitinib, which is already used in treating kidney cancer patients. AGS-003 is being s... |
| 05.07.2011 | Argos Therapeutics Presents New Phase 2 Data Showing its Arcelis™ Immunotherapy AGS-003 in Combination with Sunitinib Improves Progression-Free Survival (PFS) in Patien | Learn More-External Link |
| 13.05.2011 | Immunotherapy technology from Argos seeks partner for kidney cancer trials | Immunotherapy induces a patient’s own immune system to fight disease. Argo’s technology, called Arcelis, works by taking the RNA from the patient’s cancer and pairing it with the patient’s dendritic cells. Dendritic cells tell the immune sy... |
| 04.05.2011 | Argos Therapeutics´ Immunotherapy Platform Based on Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation | Learn More-External Link |
| 29.03.2011 | North Carolina vaccine developer Chimerix names Trost new CFO | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| 01.10.2010 | Argos Therapeutics´ Arcelis™ Immunotherapy for Renal Cell Carcinoma Demonstrates Encouraging Results in Phase 2 Combination Study with Sunitinib | Learn More-External Link |
| 21.11.2008 | Argos Therapeutics Completes $35.2 Million Series C Financing | Learn More-External Link |
| 23.04.2008 | Argos Therapeutics Secures $35.2 Million Series C Financing | |
| 20.04.2007 | Argos Therapeutics Raises $5.0 Million in Debt Financing | Learn More-External Link |
| - | Argos Therapeutics IPO would raise up to $86 million | Immunotherapy company Argos Therapeutics has filed for an initial public stock offering that could raise up to $86.2 million.
The Durham, North Carolina-based company has a developed a personalized medicine platform technology whose first t... |
| - | No IPO for immunotherapy company Argos Therapeutics | Immunotherapy company Argos Therapeutics has pulled back on its plans for an initial public offering and leaves it needing to find another way to finance phase 3 clinical trials for its novel kidney cancer treatment.
In a letter filed with ... |
| - | Argos raises $25M for kidney cancer immunotherapy phase 3 study | Immunotherapy company Argos Therapeutics, which last month withdrew plans for a $65 million initial public offering, has now secured a $25 million round of financing to start phase 3 clinical trials on its novel kidney cancer treatment.
For... |
| - | Experimental lupus therapy from Argos in partnering talks after strong phase 1 | The experimental lupus treatment being developed by Argos Therapeutics is showing promise in early stage clinical trials, but the questions remain whether it’s enough progress to attract interest from a potential pharmaceutical partner.
Arg... |
| - | What Argos Therapeutics plans to do with $86M from an IPO | Immunotherapy company Argos Therapeutics plans to start enrolling patients in a phase 3 kidney cancer trial for its lead candidate in the fourth quarter.
But first, Argos needs money. The company has just over $3 million in cash on hand, ac... |
| - | North Carolina vaccine developer Chimerix names Trost new CFO | Vaccine developer Chimerix has added life sciences industry veteran Timothy Trost to its management team.
Durham, North Carolina-based Chimerix has named Trost to the newly created position of senior vice president, chief financial officer.... |
| - | Immunotherapy technology from Argos seeks partner for kidney cancer trials | Immunotherapy company Argos Therapeutics has developed a new technology that could set it apart from other biotechnology cancer treatments — an approach that’s completely personalized to the patient and also costs less. But that’s just the ... |
| - | Personalized immunotherapy could signal first combination treatment for renal cell carcinoma patients | It’s been a few months since Dendreon got slammed for providing inconsistent data analysis to U.S. regulators for Provenge, its therapeutic cellular immunotherapy for prostate cancer. As Argos Therapeutics recruits the first set of particip... |
